Palliation of Dyspnea With Mouth Piece Ventilation in AECOPD
Primary Purpose
COPD Exacerbation, Dyspnea
Status
Terminated
Phase
Not Applicable
Locations
Finland
Study Type
Interventional
Intervention
Trilogy 100 ® (Philips Respironics)
Sponsored by
About this trial
This is an interventional treatment trial for COPD Exacerbation
Eligibility Criteria
Inclusion Criteria:
- a previous diagnosis of COPD
- hospitalized due to acute exacerbation of COPD
- at least moderate dyspnea (NRS = Numeric Rating Scale ≥ 4)
- no acute hypoventilation (pH ≥ 7.35 and PCO2 ≤ 6.0 kPa)
- able to understand the study and to give informed consent
Exclusion Criteria:
- unable to participate and use MPV due to e.g. delirium or lack of co-operation
- acute hypoventilation (pH < 7.35 or PCO2 > 6.0 kPa)
- acute need for ventilatory support
- the cause of the dyspnea can be successfully treated
- unable to give informed consent
- a previous chronic hypoxemic or hypercapnic respiratory insufficiency that has been treated on a long-term basis also at home
Sites / Locations
- Dpt of Respiratory Medicine, Tampere University Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
MPV-arm
Arm Description
Subjects use mouth piece ventilation (MPV) according to their will for 24 hours to alleviate dyspnea.
Outcomes
Primary Outcome Measures
Change in dyspnea after initial period of using MPV
Change in dyspnea after initial period of using MPV
Secondary Outcome Measures
Change in dyspnea after 24 hours of using MPV
Change in dyspnea after 24 hours of using MPV
Proportion of subjects having side-effects or not being compliant with MPV
Proportion of subjects having side-effects or not being compliant with MPV
Proportion of subjects gaining from MPV
Proportion of subjects gaining from MPV
Proportion of subjects willing to continue on MPV after the intervention
Proportion of subjects willing to continue on MPV after the intervention
Full Information
NCT ID
NCT03025425
First Posted
January 17, 2017
Last Updated
October 18, 2021
Sponsor
Tampere University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03025425
Brief Title
Palliation of Dyspnea With Mouth Piece Ventilation in AECOPD
Official Title
Palliation of Dyspnea With Mouth Piece Ventilation in Acute Exacerbation of COPD Without Respiratory Insufficiency
Study Type
Interventional
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Terminated
Why Stopped
Difficulty in finding suitable patients
Study Start Date
January 2017 (Actual)
Primary Completion Date
August 1, 2020 (Actual)
Study Completion Date
August 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tampere University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
An uncontrolled feasibility study on using mouth piece ventilation in palliation of dyspnea in subjects with acute exacerbation of COPD without acute hypercapnic respiratory failure. Subjects are recruited from the local respiratory ward. The main outcomes are the compliance of the subjects with the treatment and alleviation of dyspnea during the treatment period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COPD Exacerbation, Dyspnea
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
MPV-arm
Arm Type
Experimental
Arm Description
Subjects use mouth piece ventilation (MPV) according to their will for 24 hours to alleviate dyspnea.
Intervention Type
Device
Intervention Name(s)
Trilogy 100 ® (Philips Respironics)
Intervention Description
Mouth piece Ventilation (MPV) using Trilogy 100 ® (Philips Respironics).
Primary Outcome Measure Information:
Title
Change in dyspnea after initial period of using MPV
Description
Change in dyspnea after initial period of using MPV
Time Frame
5-60 min
Secondary Outcome Measure Information:
Title
Change in dyspnea after 24 hours of using MPV
Description
Change in dyspnea after 24 hours of using MPV
Time Frame
24 hours
Title
Proportion of subjects having side-effects or not being compliant with MPV
Description
Proportion of subjects having side-effects or not being compliant with MPV
Time Frame
24 hours
Title
Proportion of subjects gaining from MPV
Description
Proportion of subjects gaining from MPV
Time Frame
24 hours
Title
Proportion of subjects willing to continue on MPV after the intervention
Description
Proportion of subjects willing to continue on MPV after the intervention
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
a previous diagnosis of COPD
hospitalized due to acute exacerbation of COPD
at least moderate dyspnea (NRS = Numeric Rating Scale ≥ 4)
no acute hypoventilation (pH ≥ 7.35 and PCO2 ≤ 6.0 kPa)
able to understand the study and to give informed consent
Exclusion Criteria:
unable to participate and use MPV due to e.g. delirium or lack of co-operation
acute hypoventilation (pH < 7.35 or PCO2 > 6.0 kPa)
acute need for ventilatory support
the cause of the dyspnea can be successfully treated
unable to give informed consent
a previous chronic hypoxemic or hypercapnic respiratory insufficiency that has been treated on a long-term basis also at home
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lauri Lehtimäki, MD
Organizational Affiliation
Tampere University Hospital, Allergy centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dpt of Respiratory Medicine, Tampere University Hospital
City
Tampere
ZIP/Postal Code
33520
Country
Finland
12. IPD Sharing Statement
Learn more about this trial
Palliation of Dyspnea With Mouth Piece Ventilation in AECOPD
We'll reach out to this number within 24 hrs